STOCK TITAN

Director at Solid Biosciences (SLDB) converts 3,440 RSUs into shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Solid Biosciences Inc. director Ian F. Smith increased his equity stake through equity compensation vesting. On July 2, 2026, he exercised restricted stock units to acquire 3,440 shares of Common Stock at a price of $0.00 per share, reflecting a conversion of vested awards rather than an open-market purchase.

The filing shows his direct holdings rose to 138,145 shares of Common Stock after the transaction, and he also holds 6,880 Restricted Stock Units. Footnotes state that restricted stock units convert to common stock on a one-for-one basis and were granted on January 2, 2026, vesting in equal quarterly installments over 12 months.

Positive

  • None.

Negative

  • None.
Insider SMITH IAN F
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Units 3,440 $0.00 --
Exercise Common Stock 3,440 $0.00 --
Holdings After Transaction: Restricted Stock Units — 6,880 shares (Direct); Common Stock — 138,145 shares (Direct)
Footnotes (1)
  1. Restricted stock units convert to common stock on a one-for-one basis. The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.
RSUs converted 3,440 shares Restricted Stock Units converted to Common Stock on July 2, 2026
Post-transaction common shares 138,145 shares Common Stock directly held by Ian F. Smith after transaction
Remaining RSUs 6,880 units Restricted Stock Units outstanding after reported conversion
Exercise price $0.00 per share Price per share for RSU conversion to Common Stock
Grant date January 2, 2026 Date RSUs were granted, vesting over 12 months
Restricted Stock Units financial
"The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
exercise or conversion financial
"transaction_action: derivative exercise/conversion"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Solid Biosciences (SLDB) director Ian F. Smith report in this Form 4?

Ian F. Smith reported the exercise of restricted stock units into common stock. He acquired 3,440 shares of Solid Biosciences Common Stock through RSU conversion, reflecting vesting of prior equity awards rather than an open-market purchase or sale.

How many Solid Biosciences shares does Ian F. Smith hold after this Form 4 transaction?

After the reported transaction, Ian F. Smith directly holds 138,145 shares of Solid Biosciences Common Stock. This total reflects his position following the conversion of 3,440 restricted stock units into common shares disclosed in the filing.

What exactly happened with the 3,440 restricted stock units in Solid Biosciences (SLDB)?

3,440 restricted stock units vested and were converted into an equal number of Solid Biosciences common shares. The conversion price per share was reported as $0.00, consistent with stock-based compensation awards that settle in stock upon vesting rather than through a cash purchase.

Does Ian F. Smith still hold unvested or outstanding restricted stock units in Solid Biosciences?

Yes. Following the reported conversion, Ian F. Smith holds 6,880 restricted stock units. Footnotes indicate these units convert to common stock on a one-for-one basis, reflecting additional equity awards that may settle in shares as they vest under their grant terms.

When were the reported restricted stock units in Solid Biosciences granted and how do they vest?

The restricted stock units were granted on January 2, 2026. According to the filing, they vest in equal quarterly installments beginning three months from the grant date, with the final installment vesting 12 months from that date, creating a one-year vesting schedule.

Is the Form 4 for Solid Biosciences (SLDB) a buy or sell signal for investors?

The Form 4 reflects an RSU exercise, not an open-market trade. It records 3,440 restricted stock units converting into common shares as part of compensation vesting, which is typically viewed as routine and not a direct buy or sell signal on the stock.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SMITH IAN F

(Last)(First)(Middle)
C/O SOLID BIOSCIENCES INC.
500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)
CHARLESTOWN MASSACHUSETTS 02129

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/02/2026M3,440A(1)138,145D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)07/02/2026M3,440 (2) (2)Common Stock3,440$0.006,880D
Explanation of Responses:
1. Restricted stock units convert to common stock on a one-for-one basis.
2. The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.
/s/ Kimberly Cornwell as attorney-in-fact for Ian F. Smith07/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)